APOB and diabetes mellitus: Apo B100 measurement also improves CHD risk prediction in people with diabetes or metabolic syndrome [24,32] and Apo B100 may provide a better assessment of on-treatment residual risk (than LDL) providing support for the notion that addition of apo B100 measurement to the routine lipid panel would improve patient management [26,31].